GLP-1 (S)

What is GLP-1 (S)?

GLP-1 (S) is a synthetic analogue of the human GLP-1 hormone, designed to bind and activate the GLP-1 receptor. This activation promotes glucose-dependent insulin secretion and inhibits glucagon release, aiding in blood sugar regulation. Additionally, GLP-1 (S) slows gastric emptying, leading to increased satiety and potential weight loss. Due to its extended half-life, GLP-1 (S) is administered once weekly, offering a convenient dosing regimen for research purposes. This compound is intended solely for scientific investigation and is not approved for human or veterinary use.

Structure

• Chemical Formula: C₁₈₇H₂₉₁N₄₅O₅₉
• Synonyms: NN9535

GLP-1 (S) Research

GLP-1 (S) in Type 2 Diabetes Management

Clinical trials have demonstrated that GLP-1 (S) significantly improves glycemic control in individuals with type 2 diabetes. In the SUSTAIN-6 trial, GLP-1 (S) reduced HbA1c levels and was associated with a lower rate of major adverse cardiovascular events compared to placebo. These findings suggest its potential role in comprehensive diabetes management. [1]

GLP-1 (S) and Weight Management

Research indicates that GLP-1 (S) may be effective in promoting weight loss among individuals with obesity. A study published in The New England Journal of Medicine reported that participants receiving GLP-1 (S) experienced significant weight reduction compared to those on placebo. This effect is attributed to its action on appetite regulation and energy intake. [2]

Cardiovascular Outcomes with GLP-1 (S)

GLP-1 (S) has been evaluated for its impact on cardiovascular outcomes in patients with type 2 diabetes. The SUSTAIN-6 trial demonstrated a significant reduction in the risk of major adverse cardiovascular events among participants treated with GLP-1 (S). These results highlight its potential cardiovascular benefits beyond glycemic control. [3]

GLP-1 (S) and Non-Alcoholic Steatohepatitis (NASH)

Emerging studies suggest that GLP-1 (S) may have therapeutic potential in treating non-alcoholic steatohepatitis (NASH). Clinical trials have shown improvements in liver enzyme levels and reductions in liver fat content among patients with NASH treated with GLP-1 (S), indicating a possible role in managing this condition. [4]

Disclaimer

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.

THIS PRODUCT IS INTENDED FOR LABORATORY RESEARCH USE ONLY. NOT FOR HUMAN OR ANIMAL CONSUMPTION.

Referenced Citations

1. Marso SP, Daniels GH, Brown-Frandsen K, et al. “GLP-1 (S) and Cardiovascular Outcomes in Patients with Type 2 Diabetes.” The New England Journal of Medicine. 2016;375(19):1834–1844. Available at: https://www.nejm.org/doi/full/10.1056/NEJMoa1607141 

2. Wilding JPH, Batterham RL, Calanna S, et al. “Once-Weekly GLP-1 (S) in Adults with Overweight or Obesity.” The New England Journal of Medicine. 2021;384(11):989–1002. Available at: https://www.nejm.org/doi/full/10.1056/NEJMoa2032183 

3. Marso SP, Bain SC, Consoli A, et al. “GLP-1 (S) and Cardiovascular Outcomes in Patients with Type 2 Diabetes.” The New England Journal of Medicine. 2016;375(19):1834–1844. Available at: https://www.nejm.org/doi/full/10.1056/NEJMoa1607141 

4. Newsome PN, Buchholtz K, Cusi K, et al. “A Placebo-Controlled Trial of Subcutaneous GLP-1 (S) in Nonalcoholic Steatohepatitis.” The New England Journal of Medicine. 2021;384(12):1113–1124. Available at: https://www.nejm.org/doi/full/10.1056/NEJMoa2028395